U.S. Public Health Service reorganizations of 1966–1973

CDC Reports First-Ever Profound Autism Prevalence Data

Retrieved on: 
Wednesday, April 19, 2023

NEW YORK, April 19, 2023 /PRNewswire/ -- The Centers for Disease Control and Prevention today reported 26.7 percent of people with autism spectrum disorder have "profound autism". It is the first time this statistic has been reported using CDC-collected data and reflects a growing awareness that "profound autism" is different from the broader "autism spectrum disorder." The report, titled "The Prevalence and Characteristics of Children with Profound Autism, 15 Sites, United States, 2000-2016," was published in the peer-reviewed scientific journal Public Health Reports, the official journal of the Office of the U.S. Surgeon General and the U.S. Public Health Service.

Key Points: 
  • It is the first time this statistic has been reported using CDC-collected data and reflects a growing awareness that "profound autism" is different from the broader "autism spectrum disorder."
  • The report, titled " The Prevalence and Characteristics of Children with Profound Autism, 15 Sites, United States, 2000-2016 ," was published in the peer-reviewed scientific journal Public Health Reports, the official journal of the Office of the U.S.
  • The report found that the percentage of 8-year-old children with profound autism among those with autism was 26.7 percent.
  • "People with profound autism consistently experience unique, devastating, and often unseen challenges that require immediate solutions, not only for them, but for their caregivers," said Judith Ursitti, president of the Profound Autism Alliance.

Health Equity Expert Winston Wong Joins CDC Foundation Board of Directors

Retrieved on: 
Wednesday, April 19, 2023

ATLANTA, April 19, 2023 /PRNewswire/ -- Winston Wong, MD, MS, scholar-in-residence at the UCLA Kaiser Permanente Center for Health Equity, has been elected to a five-year term on the board of directors of the CDC Foundation.

Key Points: 
  • ATLANTA, April 19, 2023 /PRNewswire/ -- Winston Wong, MD, MS, scholar-in-residence at the UCLA Kaiser Permanente Center for Health Equity, has been elected to a five-year term on the board of directors of the CDC Foundation.
  • Throughout his 40-year career with roles in clinical medicine, health administration, data and policy development and healthcare philanthropy, Wong has been dedicated to improving health equity and addressing socioeconomic and racial/ethnic disparities in health.
  • During his time at Kaiser Permanente, Wong developed partnerships with communities to address health equity through enhancing population health and the dissemination of evidence-based medicine.
  • At the National Academies of Sciences, Engineering, and Medicine, Wong chairs the Roundtable on Health Equity and has served on the Board of Population Health and Public Health Practice.

SAB Biotherapeutics Provides Company Update for Full Year 2022

Retrieved on: 
Friday, March 31, 2023

SIOUX FALLS, S.D., March 31, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics ( Nasdaq: SABS ), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human immunoglobulin (hIgG) antibodies, also known as fully-human polyclonal antibodies, without the need for human donors, today reported financial results for the full year ended December 31, 2022, and provided a company update.

Key Points: 
  • SIOUX FALLS, S.D., March 31, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics ( Nasdaq: SABS ), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human immunoglobulin (hIgG) antibodies, also known as fully-human polyclonal antibodies, without the need for human donors, today reported financial results for the full year ended December 31, 2022, and provided a company update.
  • C. diff is a devastating disease recognized by the CDC as an urgent antibiotic resistance threat,” said Eddie J. Sullivan, Ph.D., Co-Founder, President, and Chief Executive Officer of SAB Biotherapeutics.
  • Cash Position: Cash and cash equivalents were $15.0 million as of December 31, 2022, compared to $33.2 million on December 31, 2021.
  • The Company will restate its prior period financial results in its Annual Report on Form 10-K for the fiscal year ended December 31, 2022.

John Nicklow Named Next President of Florida Tech

Retrieved on: 
Thursday, March 30, 2023

“I want to thank the Florida Tech community for being engaged in the search,” Nicklow said.

Key Points: 
  • “I want to thank the Florida Tech community for being engaged in the search,” Nicklow said.
  • “I believe Florida Tech is at an inflection point, and that presents a wonderful opportunity for the university,” Nicklow said.
  • This will also help us become the preferred partner for businesses, industry and government.”
    “I’m thrilled for Florida Tech and the larger community that the board of trustees has selected as its new president Dr. John Nicklow.
  • “Florida Tech is a university with a proud past and a very bright future,” Nicklow said.

Former FDA Senior Officials Join Greenleaf Health: Sandra Kweder, M.D., former Deputy Director of FDA’s Office of New Drugs & Donald D. Ashley, J.D., former Director of CDER’s Office of Compliance

Retrieved on: 
Thursday, February 2, 2023

Kweder and Ashley each bring unique subject matter expertise that expands Greenleaf's unmatched regulatory advising capabilities.

Key Points: 
  • Kweder and Ashley each bring unique subject matter expertise that expands Greenleaf's unmatched regulatory advising capabilities.
  • Dr. Sandra Kweder is an internal medicine expert with more than 30 years of experience in U.S. and international medical products regulation and policy.
  • Prior to her work in Europe, Sandy spent nearly 14 years as the Deputy Director of CDER’s Office of New Drugs.
  • “It was difficult to leave FDA, so full of dynamic, intelligent, committed experts – I never had a dull moment in over 30 years.

Acadia Pharmaceuticals Appoints Adora Ndu, Pharm.D., J.D. to its Board of Directors

Retrieved on: 
Thursday, October 13, 2022

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Adora Ndu, Pharm.D., J.D.

Key Points: 
  • Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Adora Ndu, Pharm.D., J.D.
  • Dr. Ndu is a biopharma executive with more than 15 years of experience in regulatory affairs and clinical development.
  • View the full release here: https://www.businesswire.com/news/home/20221013005276/en/
    We are pleased to welcome Dr. Ndu to Acadias Board, said Stephen R. Biggar, M.D., Ph.D., Chairman of Acadias Board of Directors.
  • I am honored to join Acadias Board of Directors.

American Osteopathic Association installs Ernest R. Gelb, DO, as 126th President

Retrieved on: 
Thursday, July 21, 2022

CHICAGO, July 21, 2022 /PRNewswire/ -- Ernest R. Gelb, DO, FACOFP, an AOA board-certified osteopathic family medicine specialist and geriatrician from Lewes, Delaware, has been installed as the 126th president of the American Osteopathic Association (AOA).

Key Points: 
  • CHICAGO, July 21, 2022 /PRNewswire/ -- Ernest R. Gelb, DO, FACOFP, an AOA board-certified osteopathic family medicine specialist and geriatrician from Lewes, Delaware, has been installed as the 126th president of the American Osteopathic Association (AOA).
  • Dr. Gelb takes office during a time of tremendous growth and expansion for the osteopathic medical profession, which includes more than 178,000 osteopathic physicians (DOs) and osteopathic medical students.
  • He is a past president of the Pennsylvania Osteopathic Medical Association (POMA) and has received multiple awards, including the Pennsylvania Osteopathic Family Physicians Society Family Physician of the Year and the POMA Distinguished Service Award.
  • The American Osteopathic Association (AOA) represents more than 178,000 osteopathic physicians (DOs) and osteopathic medical students; promotes public health; encourages and funds scientific research; serves as the primary certifying body for DOs; and is the accrediting agency for colleges of osteopathic medicine.

Lachman Consultant Services, Inc. Names Marty Shimer as Executive Director, Regulatory

Retrieved on: 
Monday, July 11, 2022

WESTBURY, N.J., July 11, 2022 /PRNewswire-PRWeb/ -- In this role, Mr. Shimer will assist clients with regulatory submissions and strategy, communications with FDA, and navigating the approval process while offering guidance on issues related to therapeutic equivalence, patent certifications, 180-day exclusivity, the Competitive Generic Therapy pathway, New Drug Application exclusivities, regulatory requirements for ANDAs and more.

Key Points: 
  • Frances Zipp, President and CEO of Lachman Consultant Services, Inc. (Lachman Consultants), a leading provider of compliance, regulatory affairs, and technical services to global life sciences organizations, announced today that CAPT Martin H. Shimer, II joined the firm as Executive Director, Regulatory, effective July 11, 2022.
  • His time with the FDA also included roles as Senior Supervisory Regulatory Management Officer, Deputy Director; Supervisory Regulatory Management Officer, Branch Chief; and Senior Regulatory Management Officer.
  • During his time with the FDA, Mr. Shimer actively supported a range of important public health initiatives, both domestically and abroad.
  • Founded in 1978, Lachman Consultants maintains three practice groups: Compliance, Regulatory Affairs, and Science and Technology.

Brand Institute Executive, a Former FDA Team Leader, Celebrates 15 Years with Company's Subsidiary, Drug Safety Institute

Retrieved on: 
Thursday, June 23, 2022

MIAMI, June 23, 2022 /PRNewswire/ -- Brand Institute , the global leader in pharmaceutical and healthcare-related name development, recently celebrated the 15-year anniversary of former FDA Team Leader, Dr. Nora Roselle, with Brand Institute/Drug Safety Institute.

Key Points: 
  • MIAMI, June 23, 2022 /PRNewswire/ -- Brand Institute , the global leader in pharmaceutical and healthcare-related name development, recently celebrated the 15-year anniversary of former FDA Team Leader, Dr. Nora Roselle, with Brand Institute/Drug Safety Institute.
  • Dr. Roselle joined Drug Safety Institute (DSI) as Managing Director of U.S. Regulatory Affairs in May 2007, and later as Vice President, Global Regulatory Affairs in 2012.
  • Dr. Roselle oversees all U.S. brand nomenclature safety assessments and FDA name submissions.
  • Drug Safety Institute (DSI) is a wholly owned subsidiary of Brand Institute that provides Brand Institute's healthcare clients with industry-leading guidance pertaining to drug name safety, packaging, and labeling.

Memorial Day Interview with Director of Library of Congress' Veterans History Project Available

Retrieved on: 
Thursday, May 19, 2022

FREDERICK, Md., May 19, 2022  /PRNewswire-PRWeb/ -- The Library of Congress Veterans History Project (VHP) is seeking to highlight veterans of the Commissioned Corps of the U.S. Public Health Service and veterans who were deployed for natural disasters or public health crises, as well as inform the public about how they can access and be a part of their veteran collection this Memorial Day season.

Key Points: 
  • The Veterans History Project collects, preserves and makes accessible the firsthand remembrances of U.S. military veterans.
  • The Veterans History Project is actively seeking the stories of Uniformed Public Health Officer veterans and military veterans who were deployed for crises response, either domestically or abroad.
  • To view the PSA for the Veterans History Project, please click here (Spanish version here).
  • Veterans History Project was created in 2000 by Congress as part of the American Folklife Center at the Library of Congress.